Skip to Content

Managing Risks with Newer Oral Small Molecules in Patients with IBD

What are the risks of treating inflammatory bowel diseases (IBD) with small oral molecules, JAK inhibitors, and Sphingosine-1-phosphate receptor modulators, and how should they be managed? In this MEDtalk, Dr. Parakkal Deepak presents his insights, published in a recent article in Current Gastroenterology Reports. He especially highlighted major adverse cardiac events and the importance of discussing this with patients.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top